Physician profile
Johnny Harris
NPI 1497166623
$4,027.91
in general payments reported to CMS, 2019-2025
29 companies · $1,258 in 2025
The $1,258 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2021: $19.89 · 2022: $535 · 2023: $992 · 2024: $998 · 2025: $1,258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,247.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $682.03 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Gilead Sciences, INC. | $606.01 | 2022-2025 | |
| Novo Nordisk INC | $552.67 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $433.14 | 2022-2025 | |
| Abbvie INC. | $284.80 | 2022-2025 | |
| Amgen INC. | $153.66 | 2019-2025 | Otezla, Repatha, Otezla |
| Exact Sciences Corporation | $146.80 | 2023-2025 | Cologuard Collection Kit |
| Viiv Healthcare Company | $122.83 | 2024-2025 | Apretude, Cabenuva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.64 | 2022-2025 | Jardiance |
| Glaxosmithkline, LLC. | $90.31 | 2022-2025 | Shingrix, Trelegy Ellipta |
| Inspire Medical Systems, INC. | $86.61 | 2025 | Inspire |
| Idorsia Pharmaceuticals US INC | $84.76 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.14 | 2022-2024 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $72.32 | 2025 | |
| Abbott Laboratories | $61.29 | 2022-2025 | Freestyle Libre 3 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $59.69 | 2023-2025 | Heplisav-B |
| Novartis Pharmaceuticals Corporation | $52.42 | 2022-2023 | |
| Verity Pharmaceuticals INC. | $52.15 | 2024 | Tlando |
| Kowa Pharmaceuticals America, INC. | $51.88 | 2025 | Zoryve |
| Merck Sharp & Dohme LLC | $47.86 | 2022-2025 | Gardasil 9, Capvaxive, Pneumovax 23 |
| Ironwood Pharmaceuticals, INC | $41.78 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $38.77 | 2022 | |
| Coloplast Corp | $24.81 | 2023 | Altis |
| Actelion Pharmaceuticals US, INC. | $24.43 | 2024 | Uptravi, Opsumit |
| Sanofi Pasteur INC. | $17.82 | 2023 | |
| Seqirus USA INC | $17.05 | 2022 | |
| Dexcom, INC. | $16.43 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.24 | 2022 | |
| Inogen, INC. | $14.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnny Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.